UBS Group Upgrades Insulet (PODD) to “Outperform”

UBS Group upgraded shares of Insulet (NASDAQ:PODD) from a market perform rating to an outperform rating in a research report report published on Monday morning, The Fly reports.

Several other research analysts have also weighed in on PODD. Barclays started coverage on Insulet in a research report on Friday, September 15th. They issued an overweight rating and a $65.00 target price on the stock. Canaccord Genuity reaffirmed a hold rating and issued a $50.00 target price on shares of Insulet in a research report on Wednesday, September 27th. Zacks Investment Research lowered Insulet from a hold rating to a sell rating in a research report on Thursday, October 5th. Wedbush reaffirmed a buy rating and issued a $65.00 target price (up from $60.00) on shares of Insulet in a research report on Tuesday, October 10th. Finally, Leerink Swann reissued an outperform rating and set a $74.00 price objective (up previously from $65.00) on shares of Insulet in a report on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $62.53.

Insulet (NASDAQ:PODD) opened at $75.83 on Monday. The company has a debt-to-equity ratio of 4.65, a current ratio of 4.88 and a quick ratio of 4.42. Insulet has a 52-week low of $38.43 and a 52-week high of $78.65. The firm has a market capitalization of $4,410.00, a PE ratio of -151.66 and a beta of 1.58.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.06. Insulet had a negative return on equity of 43.85% and a negative net margin of 6.66%. The company had revenue of $121.80 million for the quarter, compared to analyst estimates of $114.02 million. During the same period in the prior year, the firm posted ($0.05) EPS. The business’s revenue was up 28.4% compared to the same quarter last year. sell-side analysts anticipate that Insulet will post -0.43 earnings per share for the current year.

In other Insulet news, Director James C. Mullen bought 2,500 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average price of $67.45 per share, for a total transaction of $168,625.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.60% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Insulet by 11.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock valued at $118,000 after purchasing an additional 235 shares during the period. SG Americas Securities LLC bought a new stake in Insulet during the 2nd quarter valued at approximately $180,000. RNC Capital Management LLC bought a new stake in Insulet during the 2nd quarter valued at approximately $225,000. Trexquant Investment LP bought a new stake in Insulet during the 3rd quarter valued at approximately $242,000. Finally, Strs Ohio boosted its stake in Insulet by 29.6% during the 3rd quarter. Strs Ohio now owns 7,000 shares of the medical instruments supplier’s stock valued at $385,000 after purchasing an additional 1,600 shares during the period.

TRADEMARK VIOLATION NOTICE: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.com-unik.info/2018/01/11/ubs-group-upgrades-insulet-podd-to-outperform.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

The Fly

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit